Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1425 of 2026 entries
View as:

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.

Phase: N/A Priority: Normal
NCT ID: NCT00576433 Org: User:
Start: 12/31/07 End: 11/30/10 Due: 11/30/11

A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)

Phase: N/A Priority: Normal
NCT ID: NCT02723071 Org: User:
Start: 05/31/05 End: 01/31/08 Due: 01/31/09

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Phase: N/A Priority: Normal
NCT ID: NCT01849666 Org: User:
Start: 09/30/13 End: 04/30/14 Due: 04/30/15

A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01964391 Org: User:
Start: 02/21/14 End: 11/25/18 Due: 11/25/19

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01966471 Org: User:
Start: 01/31/14 End: 06/04/21 Due: 06/04/22

An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

Phase: N/A Priority: Normal
NCT ID: NCT06675955 Org: User:
Start: 12/13/24 End: 12/31/29 Due: 12/31/30

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

Phase: N/A Priority: Normal
NCT ID: NCT04603807 Org: User:
Start: 09/30/21 End: 12/01/27 Due: 12/01/28

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Phase: N/A Priority: Normal
NCT ID: NCT01000610 Org: User:
Start: 03/17/08 End: 05/16/12 Due: 05/16/13

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Phase: N/A Priority: Normal
NCT ID: NCT05619744 Org: User:
Start: 01/23/23 End: 03/04/25 Due: 03/04/26

A Prospective Study to Assess the Screening Value of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for the Identification of Patients That Benefit From Additional Cardiac Testing Prior to Vascular Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00519961 Org: User:
Start: 02/28/07 End: 09/30/10 Due: 09/30/11

A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT01371162 Org: User:
Start: 06/30/11 End: 12/31/11 Due: 12/31/12

A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01263704 Org: User:
Start: 07/17/11 End: 04/03/17 Due: 04/03/18

A Bioavailability and Pharmacokinetic Study of Subcutaneous and Intravenous RO6811135 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01802853 Org: User:
Start: 05/31/13 End: 06/30/13 Due: 06/30/14

European, Open-label, Prospective, Multinational, Multicenter Study in Adult Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home Setting is Considered Routine Practice.

Phase: N/A Priority: Normal
NCT ID: NCT02105103 Org: User:
Start: 10/31/13 End: 03/31/15 Due: 03/31/16

A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)

Phase: N/A Priority: Normal
NCT ID: NCT00517530 Org: User:
Start: 09/30/07 End: 11/30/13 Due: 11/30/14

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02924883 Org: User:
Start: 09/26/16 End: 02/06/20 Due: 02/06/21

A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT05208840 Org: User:
Start: 09/15/23 End: 01/31/26 Due: 01/31/27

A Study to Investigate the Effect of Rifampicin on the PK of Multiple Doses of Balovaptin In Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03586726 Org: User:
Start: 07/24/18 End: 11/15/18 Due: 11/15/19

A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02093000 Org: User:
Start: 11/30/14 End: 01/31/18 Due: 01/31/19

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Phase: N/A Priority: Normal
NCT ID: NCT01887886 Org: User:
Start: 12/31/13 End: 02/28/15 Due: 02/28/16

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Phase: N/A Priority: Normal
NCT ID: NCT01609075 Org: User:
Start: 06/30/12 End: 06/30/13 Due: 06/30/14

A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)

Phase: N/A Priority: Normal
NCT ID: NCT02534311 Org: User:
Start: 10/13/15 End: 12/01/15 Due: 12/01/16

A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.

Phase: N/A Priority: Normal
NCT ID: NCT02023125 Org: User:
Start: 12/31/13 End: 03/31/14 Due: 03/31/15

A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00269113 Org: User:
Start: 09/30/98 End: 04/30/09 Due: 04/30/10

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Phase: N/A Priority: Normal
NCT ID: NCT04740918 Org: User:
Start: 06/07/21 End: 06/19/24 Due: 06/19/25